Reply to the editor:  by Antonio Maria Calafiore, 
LETIERS TO THE EDITOR 
Off-pump internal thoracic artery-left anterior 
descending coronary artery grafting via small anterior 
thoracotomy: When and compared to what? 
To the Editor: 
We read with interest the article by Calafiore and associates 
on the midterm results after minimally invasive coronary 
surgery (J Thorac Cardiovasc Surg 1998;115:763-71). 
The authors deserve credit for having popularized grafting 
of the left internal thoracic artery (ITA) to the left anterior 
descending coronary artery (LAD). There is some concern, 
however, about patient selection and patient mix in the study 
population, on which the analyses in the paper are based. It is 
uncommon to find an indication for single LAD grafting in 
patients with multiple-vessel disease. Indeed, on page 764 the 
authors state that patients who are eligible for such an opera-
tion form a "very select" group of all patients having multiple-
vessel disease. It is therefore surprising that the authors man-
aged to find 220 patients of this rare category selected for 
their study, an even larger group than the single-LAD group 
(214 patients). The total number of patients who underwent 
coronary artery bypass grafting in that period was not men-
tioned. Also, there may have been some special referrals. 
More important, in the presentation of the results the two 
groups are largely combined. 
This makes generalization of the results questionable. The 
extraordinary nature of this large group of patients with mul-
tiple-vessel disease, treated with single-LAD grafting, is illus-
trated by the apparent absence of a material difference in 
functional outcome. It should be noted, however, that this per-
tains to midterm outcome only. Differences in outcome may 
well become visible on long-term follow-up. 
The authors should consider presenting their data strictly 
separately for single- and multiple-vessel groups. The multi-
ple-vessel group in the present study should be regarded with 
caution, because this necessarily is a highly atypical group of 
patients. If not, the findings challenge the basic concept of 
surgical myocardial revascularization, that is, complete revas-
cularization. Still, the long-term follow-up of this atypical 
group is of clear interest. In its present form the results of the 
report are difficult to interpret and may lead to confusion. 
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Reply to the Editor: 
The relatively high number of patients with multiple-vessel 
disease in the population that underwent single LAD grafting 
described in our recent article (J Thorac Cardiovasc Surg 
1998;115:763-71) disturbed more than one surgeon. The idea 
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Fig 1. Coronary angiogram showing a severely diseased 
LAD. The huge marginal branch is free of significant lesions, 
but the distal circumflex artery shows a severe stenosis fol-
lowed by a small terminal branch. 
to leave a diseased coronary vessel ungrafted seems to be a 
strategic mistake. 
However, the inclusion of this "very select group" of 
patients depends on the definition of "diseased vessel" and of 
"complete revascularization." 
My definition of "diseased vessel" is the following: A ves-
sel is considered "diseased" if it is the main vessel of the ter-
ritory or if a side branch of it is occluded or if it has a lesion 
equal to or greater than 70%. If a circumflex artery or a right 
coronary artery has a short and small posterolateral branch 
with such lesions, the circumflex artery or the right coronary 
artery has to be defined as "diseased." In Fig 1, a coronary 
angiogram is shown in which the LAD has severe disease; the 
huge marginal branch is free of significant lesions, but the dis-
tal circumflex artery shows a severe stenosis followed by a 
small terminal branch. This patient has 2-vessel disease, but I 
would never graft this small branch which, in my opinion, has 
no influence on the patient's future. I certainly would never 
use cardiopulmonary bypass for such a purpose. 
The concept of "complete revascularization" needs a more 
thorough analysis. If with this term we mean that any lesion 
that causes ischemia to the patient should be grafted, I fully 
agree. If this definition also includes the necessity to graft 
major and important coronary vessels supplying a huge terri-
tory and with a significant (~70%) lesion, even if there is no 
clearly demonstrated ischemia, when concomitant grafting to 
other surely ischemic territories is performed, I fully agree. 
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But if with this tenn we state that any stenotic vessel has to be 
grafted, regardless of its importance and size, without any 
demonstration of ischemia in the territory, this definition of 
"complete revascularization" has to be forgotten. Today we 
have at our disposition many tools to properly investigate the 
importance of a stenosis, and complete revascularization 
(interventional, surgical, or combined) of all ischemic territo-
ries is always our goal. However, the timing can change and 
the strategy can differ from patient to patient. 
In our article I thought that the real problem was focused 
not on the surgical indication (single LAD disease or multi-
ple-vessel disease), which can be debatable, but on the future 
of the graft. (Is this approach able to guarantee satisfying per-
meability of the graft? Can this strategy be considered safe 
and reproducible?) For this reason I mixed all my patients, but 
the patients with "multiple-vessel disease" in this group, with 
only a few exceptions (hybrid procedures), are not the same 
patients we operate on every day in our daily practice. 
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The use of the calcium antagonist nicardipine in 
arterial coronary bypass surgery 
To the Editor: 
In the December 1998 issue of the Journal, Acar, l Possati,2 
and their associates independently provided important data on 
the 5-year patency rate of the radial artery graft. 
Both groups acknowledge the impressive spastic character-
istics of this arterial conduit and advocate peri operative 
release of spasm and routine administration of the calcium 
antagonist diltiazem to the patients for 1 year or more. 
Interruption of this treatment after 1 year or later during fol-
low-up did not seem to adversely influence either clinical out-
come or 5-year patency. This observation is related to the 
apparent loss of reactivity of the radial graft over time. 
The use of antispasmodic drugs for patients receiving arte-
rial grafts is a common practice, although so far no study has 
demonstrated its value on the surgical outcome, keeping in 
mind that "spasm" may be confounded by other factors such 
as surgical technique, familiarity with arterial grafts, and peri-
operative conduit preparation. Since 1994, we have been 
using nicardipine hydrochloride, the first intravenously 
administered dihydropyridine calcium channel antagonist, for 
sequential or bilateral internal thoracic artery grafting. The 
patients are started perioperatively on intravenous nicardipine 
hydrochloride (0.25 Ilg/kg per minute) after a 1 mg intra-
venous bolus. The drug is titrated according to the systemic 
vascular resistance and discontinued on the second postoper-
ative day. For patients receiving a radial artery graft, we added 
to this protocol gentle hydrostatic dilatation of the conduit 
with 1 % papaverine and oral administration of nicardipine 20 
to 30 mg three times a day after discontinuation of intra-
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venous perfusion on day 2. The first 50 patients undergoing 
myocardial revascularization with a radial graft using that 
protocol were observed. A total of 150 anastomoses were per-
fonned with a mean of 3.0 anastomoses per patient, and 108 
arterial grafts were used for the completion of 111 coronary 
distal anastomoses. Fifty radial arteries were used for 52 dis-
tal anastomoses, and 36 venous grafts were used for 39 distal 
anastomoses. The radial artery was placed on the obtuse mar-
ginal branch in 58% of cases, diagonal branches in 13%, and 
the right coronary artery in 29%. Proximal anastomoses were 
done directly on the aorta in 80% of cases. 
The operative mortality was 4% because of 2 cases of ful-
minant pulmonary sepsis. There was no evidence of perioper-
ative myocardial infarction or arterial graft hypoperfusion 
syndrome. Mean creatine kinase MB level at 18 hours was 36 
IlgIL. Neither ischemic anomalies of the electrocardiogram 
nor wall motion abnonnalities on discharge transthoracic 
echocardiography were detected. Angiography perfonned in 
the last 20 patients showed a 98% (51/52) penneability rate 
for all grafts. Nineteen of 20 radial grafts were patent. A mod-
erate spasm (40%) developed in the middle part of the conduit 
in one radial artery. 
Our experience with the radial artery is part of a larger 
experience with the perioperative use of nicardipine in more 
than 550 cases of bilateral or sequential internal thoracic 
artery grafting. This protocol has virtually eliminated internal 
thoracic artery spasm or hypoperfusion in our practice. 
Nicardipine has several potential advantages over diltiazem. 
Nicardipine is a more potent and selective arteriolar vasodila-
tory agent, which also has the capability to inhibit endothelin-
induced vasoconstriction.3 This drug has neither chronotrop-
ic, dromotropic, nor inotropic negative effects. Its short action 
duration makes it convenient for perioperative management, 
and it is well tolerated in association with ~ blockers in the 
routine management of patients with coronary artery disease. 
Nicardipine also has a documented cardioprotective effect on 
ischemic myocardium, and some data suggest cardioprotec-
tive effects during cardioplegic cardiac arrest.4 We therefore 
suggest that the time has come to assess the real need for anti-
spasmodic drugs in arterial coronary bypass grafting and to 
determine the most adequate pharmacologic management for 
patients receiving arterial grafts such as the radial artery. 
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